Home >  Pulmonology MDTV >  Pulmonology Shorts >  Role of Hormone...

Role of Hormone Replacement Therapy in Managing Pulmonary Hypertension for Women: Study

By - Anshika Mishra
Published On 2024-05-21 02:30 GMT   |   Update On 2024-05-21 08:34 GMT
Advertisement
Researchers estimate that about 1% of the global population has pulmonary hypertension — a disease caused by high blood pressure in the blood vessels that deliver oxygen to the lungs.
Now, according to research presented at the ATS 2024 International Conference, the use of hormone replacement therapy (HRT) may be associated with improved pulmonary hypertension in women.
Hormone replacement therapy (HRT) may offer potential benefits for women with pulmonary hypertension. Estrogen, a key hormone in HRT, has been found to have vasodilatory effects, meaning it can help relax and widen blood vessels, improving blood flow and reducing the strain on the heart. Additionally, HRT may help address symptoms of menopause that can exacerbate the condition, such as fatigue and reduced exercise capacity.
In this study, researchers recruited 742 female participants and classified those with pulmonary hypertension into the five groups established by the World Symposium on Pulmonary Hypertension:
Group 1: Pulmonary arterial hypertension
Group 2: Pulmonary hypertension caused by left heart disease
Group 3: Pulmonary hypertension caused by lung disease
Group 4: Pulmonary hypertension from chronic blood clots in the lungs
Advertisement
Group 5: Pulmonary hypertension from unknown causes
The impact of both exogenous and endogenous hormone exposure on pulmonary hypertension across these groups were examined.
Upon analysis, researchers discovered that average pulmonary arterial pressure decreased with a greater lifetime duration of menstruation across all pulmonary hypertension groups. They also found that hormone replacement therapy (HRT) was associated with lower mean pulmonary artery pressure, higher right ventricular fractional shortening, and improved right ventricular ejection fraction.
Specifically, those in pulmonary hypertension Group 1 showed lower mean pulmonary artery pressure, reduced pulmonary vascular resistance, and higher right ventricular ejection fraction when exposed to HRT.
“Our preliminary data indicates that hormone replacement therapy (HRT) improves mean pulmonary arterial pressure, pulmonary vascular resistance, right ventricular ejection fraction, and right ventricular fractional shortening in women with pulmonary hypertension. No differences were observed in healthy controls or with increased lifetime duration of menses. These findings support the hypothesis that hormones may be protective, especially notable in Group 1 pulmonary hypertension. Further studies are needed to explore this,” said Audriana Hurbon, assistant clinical professor in the Department of Medicine at The University of Arizona College of Medicine Tucson and corresponding author of the study.
Reference: A. Hurbon, G.J. Beck, S.C. Erzurum, R.P. Frantz, G. Grunig, P.M. Hassoun, A. Hemnes, N. Hill, E. Horn, C. Jellis, B. Larive, J. Leopold, M. Park, E.B. Rosenzweig, F.P. Rischard, and PVDOMICS Study Group. The Impact of Reproductive History on Pulmonary Hypertension: Insights From the Pvdomics Study (abstract). Am J Respir Crit Care Med 2024;209:A2748.
Full View
Tags:    
Article Source : ATS 2024 International Conference

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Anshika Mishra

Anshika Mishra is a dedicated scholar pursuing a Masters in Biotechnology, driven by a profound passion for exploring the intersection of science and healthcare. Having embarked on this academic journey with a passion to make meaningful contributions to the medical field, Anshika joined Medical Dialogues in 2023 to further delve into the realms of healthcare journalism.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Micro labs to offer mucolytic solution for respiratory care with its recently launched Pulmucus range

Why Asthma Often Comes Back After Stopping Biologic Drugs? Study Sheds Light

Digital Inhalers May Predict COPD Flare-Ups: Study Finds

New Nanoparticles Therapy for Patients with Lung Cancer, Cystic Fibrosis: Study Finds

One in Ten Asthma Cases Linked to Harmful Urban Environments: Study

Is Your Lung Health Declining Earlier Than You Think? Study Sheds Light

Can Just a Few Nights of Poor Sleep Increase Your Risk of Heart Disease? Study Finds Out

7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice